1 World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing. WHO, 2009
[2]
2 World Health Organization. Global Tuberculosis Control 2010. WHO, 2010
[3]
3 Nuermberger E L, Spigelman M K, Yew W W. Current development and future prospects in chemotherapy of tuberculosis. Respirology, 2010, 15: 764-778？？
[4]
4 Masihi K N. Fighting infection using immunomodulatory agents. Expert Opin Biol Ther, 2001, 1: 641-653？？
[5]
5 Urdahl K B, Shafiani S, Ernst J D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol, 2011, 4: 288-293？？
[6]
6 Cooper A M, Mayer-Barber K D, Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol, 2011, 4: 252-260？？
[7]
8 Coleman D L, Chodakewitz J A, Bartiss A H, et al. Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood, 1988, 72: 573-578
[8]
9 Suzuki K, Lee W J, Hashimoto T, et al. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin Exp Immunol, 1994, 98: 169-173
[9]
10 Berretta F, St-Pierre J, Piccirillo C A, et al. IL-2 contributes to maintaining a balance between CD4+ Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. J Immunol, 2011, 186: 4862-4871？？
[10]
11 Yamamura M, Uyemura K, Deans R J, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science, 1991, 254: 277-279？？
[11]
12 Wnr R C, Liu Y M, Schluger N W. Local immune responses correlated with presentation and outcome in tuberculosis. Am J Respir Crit Care Med, 1998, 157: 729-735
[12]
13 Tan Q, Xie W P, Min R, et al. Characterization of Th1- and Th2-type immune response in human multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 2012, 31: 1233-1242？？
[13]
14 Cai H, Yu D H, Tian X, et al. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol, 2005, 24: 605-613？？
[14]
15 Nambiar J K, Ryan A A, Kong C U, et al. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol, 2010, 40: 153-161
[15]
16 Zhuang Y, Li G, Zhang X, et al. Study of recombinant IL-2 on Mycobacterium tuberculosis infected mice. Xian Dai Mian Yi Xue, 1992, 12: 3
[16]
17 Chun N H, Zhu L Z, Yie Z Z, et al. A controlled clinical study on the efficacy of recombinant human interleukin-2 in the treatment of pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi, 2003, 26: 548-551
[17]
18 Bermudez L E, Martinelli J, Petrofsky M, et al. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis, 1994, 169: 575-580？？
[18]
19 Pedral-Sampaio D B, Netto E M, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis, 2003, 7: 245-252
[19]
20 Lu J, Yue J, Wu J, et al. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis. Pharmacology, 2010, 85: 365-371？？
[20]
21 Watson V E, Hill L L, Owen-Schaub L B, et al. Apoptosis in Mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Pathol, 2000, 190: 211-220？？
[21]
22 Liang Y, Wu X, Zhang J, et al. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. Scand J Immunol, 2011, 74: 42-46？？
[22]
23 Liang Y, Wu X, Zhang J, et al. The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin. Vaccine, 2008, 26: 4536-4540？？
[23]
24 Aslanzadeh J, de la Viuda M, Fille M, et al. Comparison of culture and acid-fast bacilli stain to PCR for detection of Mycobacterium tuberculosis in clinical samples. Mol Cell Probes, 1998, 12: 207-211？？
[24]
7 Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol, 2009, 157: 235-243？？
[25]
25 Gebre N, Karlsson U, Jonsson G, et al. Improved microscopical diagnosis of pulmonary tuberculosis in developing countries. Trans R Soc Trop Med Hyg, 1995, 89: 191-193？？
[26]
26 Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood, 2011, 117: 2783-2790？？
[27]
27 Katsikis P D, Mueller Y M, Villinger F. The cytokine network of acute HIV Infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog, 2011, 7: e1002055
[28]
28 Szeliga J, Daniel D S, Yang C H, et al. Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis. Tuberculosis (Edinb), 2008, 88: 7-20？？
[29]
29 Toubaji A, Hill S, Terabe M, et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long-term tumor protection. Vaccine, 2007, 25: 5882-5891？？
[30]
30 Ahlers J D, Dunlop N, Alling D W, et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol, 1997, 158: 3947-3958
